Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial (NCCH1508,REMORA trial) - Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma (NCCH1508,REMORA trial)

ational Cancer Center0 sites42 target enrollmentStarted: March 30, 2017Last updated: October 17, 2023

Conditions

Trial Snapshot

No summary available.

•1) Active double cancer; synchronous or metachronous within 5years. Patients with carcinoma in situ are eligible 2) Infections requiring systemic therapy 3) Fever of >=38 degrees Celsius at the time of registration 4) Active hemoptysis (more than half a teaspoon of blood) within 21days before registration 5) Interstitial pneumonia and/or pulmonary fibrosis diagnosed by chest CT imaging or clinical examinations 6) Grade >=2 adverse reactions caused by prior therapy except any grade of alopecia 7) History of any of the followings; unstable angina within 6 months before registration, heart attack, pulmonary embolism, deep vein thrombosis, brain bleeding, cerebral infarction, transient ischemic attacks within 6 months before registration and arterial thromboembolism 8) HIV antibody positive 9) Pregnant or breast-feeding women, or women suspected of being pregnant 10) Mental disease interfering taking part in the trial 11) Taking continuous systemic steroids and/or other immunosuppressive drugs (orally or intravenously)

Sponsor

ational Cancer Center